Pages that link to "Q38958215"

The following pages link to Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis (Q38958215):

Displayed 50 items.

• Secukinumab for rheumatology: development and its potential place in therapy (Q26738523) ‎ (← links)
• Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials (Q26746100) ‎ (← links)
• Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials (Q26766567) ‎ (← links)
• Profile of secukinumab in the treatment of psoriasis: current perspectives (Q26776303) ‎ (← links)
• Secukinumab: A New Treatment Option for Psoriatic Arthritis (Q28066204) ‎ (← links)
• Treatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumab (Q28069819) ‎ (← links)
• T Helper Cell Subsets in Clinical Manifestations of Psoriasis (Q28069848) ‎ (← links)
• Secukinumab for ankylosing spondylitis and psoriatic arthritis (Q28071474) ‎ (← links)
• Recent advances in understanding and managing psoriatic arthritis (Q28076527) ‎ (← links)
• The Changing Face of Clinical Trials in Psoriatic Arthritis (Q30235002) ‎ (← links)
• Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders (Q30399745) ‎ (← links)
• Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype (Q33553954) ‎ (← links)
• Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System (Q33770508) ‎ (← links)
• Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics (Q33809045) ‎ (← links)
• Neutrophil extracellular traps exacerbate Th1-mediated autoimmune responses in rheumatoid arthritis by promoting DC maturation (Q33811944) ‎ (← links)
• Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials (Q33844447) ‎ (← links)
• Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled perio (Q34538249) ‎ (← links)
• Higher efficacy of anti-IL-6/IL-21 combination therapy compared to monotherapy in the induction phase of Th17-driven experimental arthritis (Q36270103) ‎ (← links)
• Latest therapeutic advances in musculoskeletal disease from the ACR 2015 annual conference. (Q36448681) ‎ (← links)
• Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity (Q37138974) ‎ (← links)
• Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by. (Q37362082) ‎ (← links)
• Ndfip1 restricts Th17 cell potency by limiting lineage stability and proinflammatory cytokine production (Q37554411) ‎ (← links)
• Anti-IL17A in Axial Spondyloarthritis-Where Are We At? (Q37590576) ‎ (← links)
• IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role. (Q37679294) ‎ (← links)
• Mechanistic rationales for targeting interleukin-17A in spondyloarthritis (Q37686009) ‎ (← links)
• Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis (Q37713522) ‎ (← links)
• Innate Immune Activation Can Trigger Experimental Spondyloarthritis in HLA-B27/Huβ2m Transgenic Rats (Q38616684) ‎ (← links)
• Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison (Q38648826) ‎ (← links)
• Raising Standards for the Evaluation of Future Psoriasis Therapeutics: A Critical Checklist. (Q38658837) ‎ (← links)
• Secukinumab (AIN-457) for the treatment of Psoriasis (Q38662868) ‎ (← links)
• Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis (Q38667430) ‎ (← links)
• Residual disease activity in psoriatic arthritis: discordance between the rheumatologist's opinion and minimal disease activity measurement (Q38679357) ‎ (← links)
• Tumor necrosis factor inhibitors in psoriatic arthritis. (Q38685543) ‎ (← links)
• Inflammation in rheumatology in 2015: New tools to tackle inflammatory arthritis (Q38695705) ‎ (← links)
• Psoriatic arthritis in 2015: Advancement continues in imaging, tight control and new drugs (Q38705872) ‎ (← links)
• Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis (Q38725225) ‎ (← links)
• Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options (Q38759376) ‎ (← links)
• Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch (Q38764424) ‎ (← links)
• Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis (Q38766379) ‎ (← links)
• Secukinumab (AIN457) in the treatment of ankylosing spondylitis (Q38777116) ‎ (← links)
• New therapies for psoriasis and psoriatic arthritis (Q38792080) ‎ (← links)
• Fungal Infections and New Biologic Therapies (Q38794862) ‎ (← links)
• New evidence on the management of spondyloarthritis. (Q38799979) ‎ (← links)
• The Bench-to-Bedside Story of IL-17 and the Therapeutic Efficacy of its Targeting in Spondyloarthritis (Q38815070) ‎ (← links)
• The safety of ustekinumab for the treatment of psoriatic arthritis (Q38820480) ‎ (← links)
• A Review of Psoriasis, Therapies, and Suicide. (Q38840271) ‎ (← links)
• The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis (Q38840275) ‎ (← links)
• Immune-mediated mechanisms of atherosclerosis and implications for the clinic (Q38851472) ‎ (← links)
• Secukinumab: A Review in Psoriatic Arthritis (Q38864743) ‎ (← links)
• Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). (Q38868356) ‎ (← links)